<bill session="116" type="h" number="534" updated="2022-11-01T14:02:54Z">
  <state datetime="2019-01-14">REFERRED</state>
  <status>
    <introduced datetime="2019-01-14"/>
  </status>
  <introduced datetime="2019-01-14"/>
  <titles>
    <title type="display">Aidan&#226;&#8364;&#8482;s Law</title>
    <title type="official" as="introduced">To amend the Public Health Service Act, in relation to requiring adrenoleukodystrophy screening of newborns.</title>
    <title type="short" as="introduced">Aidan&#226;&#8364;&#8482;s Law</title>
  </titles>
  <sponsor bioguide_id="C001067"/>
  <cosponsors>
    <cosponsor bioguide_id="E000296" joined="2019-04-12"/>
    <cosponsor bioguide_id="L000397" joined="2019-04-12"/>
    <cosponsor bioguide_id="L000480" joined="2019-12-04"/>
    <cosponsor bioguide_id="R000515" joined="2019-04-04"/>
    <cosponsor bioguide_id="Z000017" joined="2019-01-14"/>
  </cosponsors>
  <actions>
    <action datetime="2019-01-14">
      <text>Introduced in House</text>
    </action>
    <action datetime="2019-01-14" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2019-01-25">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
    <committee code="HSIF14" name="House Energy and Commerce" subcommittee="Health" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Advisory bodies"/>
    <term name="Child health"/>
    <term name="Health promotion and preventive care"/>
    <term name="Hereditary and development disorders"/>
    <term name="Medical tests and diagnostic methods"/>
    <term name="Neurological disorders"/>
  </subjects>
  <amendments/>
  <summary date="2019-08-28T14:12:03Z" status="Introduced in House">Aidan's Law

This bill authorizes newborn screenings for adrenoleukodystrophy (also known as ALD), which is a hereditary condition that damages the insulating membrane of nerve cells in the brain. The bill authorizes hospitals, child care centers, clinics, and similar institutions to test newborns for ALD in accordance with state protocols; such protocols must be approved by the Discretionary Advisory Committee on Heritable Disorders in Newborns and Children.

The bill also reauthorizes for FY2020-FY2023 the heritable disorders screening program for newborns and children that is administered by the Health Resources and Services Administration.</summary>
</bill>
